ClinicalTrials.gg
CompletedNCT03345849U-EXCELUpdated Nov 23, 2022Results posted

A Study of the Efficacy and Safety of Upadacitinib in Participants With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Conventional and/or Biologic Therapies

A Phase 3 interventional study of Upadacitinib and Placebo for Upadacitinib in Crohn's Disease, sponsored by AbbVie. Completed at 432 sites in 49 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2022-11-23.

Sponsored by AbbVie · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
526
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 55 studies in Crohn Disease by AbbVie — 6 open to participants now, 14 under way, 6 of them phase 3. Crohn Disease · AbbVie.

Enrollment
9th of 27
526 · median 220
Started
2017
with 5 others
Phase 3
16 of 55
1 open now
Registered
32nd of 55
by date

Among the 55 studies in Crohn Disease by AbbVie, this one is the 9th largest by enrollment of the 27 interventional ones that give a count, is one of 6 that started in 2017, is one of 16 in phase 3, and was the 32nd registered.

Crohn Disease

1,993 studies on the registry are indexed under Crohn Disease; 478 are open to participants now.

Browse Crohn Disease studies →

Open to participants now

6 of the 55 studies in Crohn Disease by AbbVie are open now, in 12 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

Who these studies take

Of the 353 Crohn Disease studies recruiting now, 154 (44%) set no upper age limit and 144 (41%) stop at 75 or younger; 95 take children under 18; 56 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 55 studies in Crohn Disease by AbbVie, or all of them as a file.
02

Study summary

The objective of this study is to evaluate the efficacy and safety of upadacitinib compared to placebo as induction therapy in adults with moderately and severely active Crohn's disease (CD).

Read the detailed description

This study includes two parts:

  • Part 1: a randomized double-blind placebo-controlled induction period and
  • Part 2: an extended treatment period for non-responders from Part 1.

In Part 1, participants will be randomized in a 2:1 ratio to upadacitinib 45 mg once daily (QD) or matching placebo for 12 weeks. The randomization will be stratified by baseline corticosteroid use (yes or no), endoscopic disease severity (Simplified Endoscopic Score for Crohn's disease [SES-CD] \< 15 and ≥ 15), and number of prior biologics with prior inadequate response or intolerance (0, 1, > 1).

Participants who do not achieve clinical response at Week 12 will be able to enroll in Part 2 to receive a double-blind extended treatment with upadacitinib until Week 24. Clinical response is defined as a ≥ 30% decrease in average daily very soft or liquid stool frequency (SF) and/or ≥ 30% decrease in average daily abdominal pain (AP) score (both not worse than Baseline).

Participants who achieve clinical response at Week 12 may be eligible to enter the 52-week, double-blind, maintenance portion of Study M14-430 (NCT03345823).

03

Conditions studied

  • Crohn's Disease

Browse trials for

Keywords

  • Upadacitinib
  • ABT-494
  • Efficacy
  • Safety
  • Crohn's Disease
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Confirmed diagnosis of CD for at least 3 months prior to Baseline.
  • Confirmed diagnosis of moderate to severe CD as assessed by stool frequency (SF), abdominal pain (AP) score.
  • Evidence of mucosal inflammation based on the Simplified Endoscopic Score for Crohn's disease (SES-CD) on an endoscopy confirmed by a central reader.
  • Demonstrated an inadequate response or intolerance to one or more conventional and/or biologic therapies (oral locally acting , intravenous or oral corticosteroids, or biologic therapies for CD), in the opinion of the investigator.

    • Note: Participants who have had inadequate response or intolerance to conventional therapy who have received prior biologic may be enrolled; however, participants must have discontinued the biologic for reasons other than inadequate response or intolerance (e.g., change of insurance, well controlled disease).
  • If female, participant must meet the recommendations.

Exclusion criteria

Exclusion Criteria:

  • Participant with a current diagnosis of ulcerative colitis or indeterminate colitis.
  • Participant not on stable doses of CD related antibiotics, oral aminosalicylates, or methotrexate (MTX).
  • Participant with the following ongoing known complications of CD: abscess (abdominal or peri-anal), symptomatic bowel strictures, fulminant colitis, toxic megacolon, > 2 entire missing segments of the following 5 segments: terminal ileum, right colon, transverse colon, sigmoid and left colon, and rectum, or any other manifestation that might require surgery while enrolled in the study.
  • Participant with ostomy or ileoanal pouch.
  • Participant diagnosed with conditions that could interfere with drug absorption including but not limited to short gut or short bowel syndrome.
  • Screening laboratory and other analyses show abnormal results.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
526 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Participants will receive placebo once daily for 12 weeks in Part 1. Clinical non-responders will receive 45 mg upadacitinib once daily for 12 weeks in Part 2.

    Drug: Upadacitinib · Drug: Placebo for Upadacitinib

  • Experimental
    Upadacitinib

    Participants will receive 45 mg upadacitinib once daily for 12 weeks in Part 1. Clinical non-responders will receive 30 mg upadacitinib once daily for 12 weeks in Part 2.

    Drug: Upadacitinib

Interventions

  • Oral; Tablet

    Also known as: ABT-494, RINVOQ

  • DrugPlacebo for Upadacitinib

    Oral; Tablet

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Clinical Remission Per Crohn's Disease Activity Index (CDAI) at Week 12

    The co-primary endpoint for United States (US)/Food and Drug Administration (FDA) regulatory purposes was clinical remission based on CDAI at Week 12. CDAI is a composite instrument that includes participant symptoms evaluated over 7 days (abdominal pain, stool frequency and general well-being), as well as presence of complications (arthritis/arthralgia, iritis/uveitis, erythema nodosum/pyoderma gangrenosum/aphthous stomatitis, anal fissure/fistula/abscess, other fistula, and fever), the use of antidiarrheal medicines, presence of an abdominal mass, hematocrit, and body weight. These items are scored individually, weighted, and do not contribute equally to the overall score. The CDAI is derived from summing up the weighted individual scores of eight items. CDAI approximately ranges from 0 to 600 with higher scores indicating more severe disease. Clinical remission is defined as a CDAI score less than 150.

    Time frame: Week 12

  2. Percentage of Participants With Clinical Remission Per Patient-Reported Outcomes (PROs) at Week 12

    The co-primary endpoint for European Union (EU)/European Medicines Agency (EMA) regulatory purposes was clinical remission defined based on two patient reported outcomes, average daily stool frequency (SF) and average daily abdominal pain score (APS). Clinical remission per PROs was defined as average daily very soft or liquid SF ≤ 2.8 and average daily APS ≤ 1.0 and neither worse than Baseline. Participants recorded APS and the number of very soft or liquid SF daily in an electronic diary. Abdominal pain was rated on a scale from 0 (none) to 3 (severe). The average daily very soft or liquid SF and APS were calculated using the 4-7 most recent useable days of patient-report outcomes (i.e., excluding days with missing entries or associated with endoscopy procedures) out of the last 14 days prior to the Week 12 visit.

    Time frame: Week 12

  3. Percentage of Participants With Endoscopic Response at Week 12

    Endoscopic response at Week 12 was a co-primary endpoint for both the US/FDA and EU/EMA regulatory purposes. Endoscopic response was defined as greater than 50% decrease in Simple Endoscopic Score for Crohn's Disease (SES-CD) from Baseline of the induction study (or for participants with an SES-CD of 4 at Baseline, at least a 2-point reduction from Baseline), as scored by independent external and blinded central readers. The SES-CD evaluates 4 endoscopic variables (ulcer size, ulcerated surface, affected surface, and narrowing, each on a scale from 0 (none) to 3 in 5 segments assessed during ileocolonoscopy (ileum, right colon, transverse colon, sigmoid and left colon, and rectum). The total score is the sum of the 4 endoscopic variable scores and ranges from 0 to 56, where higher scores indicate more severe disease.

    Time frame: Baseline and Week 12

Secondary outcomes

  1. Percentage of Participants With Endoscopic Remission at Week 12

    Endoscopic remission is defined as an SES-CD ≤ 4 and at least 2 point reduction from Baseline and no subscore \> 1 in any individual variable,as scored by independent external and blinded central readers. The SES-CD evaluates 4 endoscopic variables (ulcer size, ulcerated surface, affected surface, and narrowing, each on a scale from 0 (none) to 3 in 5 segments assessed during ileocolonoscopy (ileum, right colon, transverse colon, sigmoid and left colon, and rectum). The total score is the sum of the 4 endoscopic variable scores and ranges from 0 to 56, where higher scores indicate more severe disease.

    Time frame: Baseline and Week 12

  2. Percentage of Participants Who Discontinued Corticosteroid Use for Crohn's Disease and Achieved Clinical Remission Per CDAI at Week 12

    Corticosteroid-free clinical remission is defined as participants who discontinued corticosteroid use for CD and achieved clinical remission per CDAI at Week 12, assessed for participants taking corticosteroids for CD at Baseline. CDAI is a composite instrument that includes participant symptoms evaluated over 7 days (abdominal pain, stool frequency and general well-being), as well as presence of complications (arthritis/arthralgia, iritis/uveitis, erythema nodosum/pyoderma gangrenosum/aphthous stomatitis, anal fissure/fistula/abscess, other fistula, and fever), the use of antidiarrheal medicines, presence of an abdominal mass, hematocrit, and body weight. These items are scored individually, weighted, and do not contribute equally to the overall score. The CDAI is derived from summing up the weighted individual scores of eight items. CDAI approximately ranges from 0 to 600 with higher scores indicating more severe disease. Clinical remission is defined as CDAI score less than 150.

    Time frame: Week 12

  3. Change From Baseline in Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-Fatigue) at Week 12

    The FACIT-Fatigue questionnaire is a self-administered patient questionnaire that consists of 13 questions designed to measure the degree of fatigue experienced by participants in the previous 7 days, including physical fatigue (e.g., I feel tired), functional fatigue (e.g., trouble finishing things), emotional fatigue (e.g., frustration), and social consequences of fatigue (e.g., limits social activity). Participants respond to the questions on a scale from 0 (not at all) to 4 (very much). The FACIT-Fatigue score is computed by summing the item scores, after reversing those items that are worded in the negative direction. The FACIT-Fatigue score ranges from 0 to 52, where higher scores represent less fatigue. A positive change from Baseline indicates improvement.

    Time frame: Baseline and Week 12

  4. Change From Baseline in Inflammatory Bowel Disease Questionnaire (IBDQ) Total Score at Week 12

    The Inflammatory Bowel Disease Questionnaire (IBDQ) is used to assess health-related quality of life (HRQoL) in patients with inflammatory bowel disease. It consists of 32 questions evaluating bowel and systemic symptoms, as well as emotional and social functions. Each question is answered on a scale from 1 (worst) to 7 (best). The total score ranges from 32 to 224 with higher scores indicating better health-related quality of life. A positive change from Baseline indicates improvement.

    Time frame: Baseline and Week 12

  5. Percentage of Participants Achieving Clinical Response 100 (CR-100) at Week 2

    Clinical response 100 (CR-100) is defined as a decrease of at least 100 points in CDAI from Baseline. CDAI is a composite instrument that includes participant symptoms evaluated over 7 days (abdominal pain, stool frequency and general well-being), as well as presence of complications (arthritis/arthralgia, iritis/uveitis, erythema nodosum/pyoderma gangrenosum/aphthous stomatitis, anal fissure/fistula/abscess, other fistula, and fever), the use of antidiarrheal medicines, presence of an abdominal mass, hematocrit, and body weight. These items are scored individually, weighted, and do not contribute equally to the overall score. The CDAI is derived from summing up the weighted individual scores of eight items. CDAI approximately ranges from 0 to 600 with higher scores indicating more severe disease.

    Time frame: Baseline and Week 2

  6. Percentage of Participants Achieving Clinical Response 100 (CR-100) at Week 12

    Clinical response 100 (CR-100) is defined as a decrease of at least 100 points in CDAI from Baseline. CDAI is a composite instrument that includes participant symptoms evaluated over 7 days (abdominal pain, stool frequency and general well-being), as well as presence of complications (arthritis/arthralgia, iritis/uveitis, erythema nodosum/pyoderma gangrenosum/aphthous stomatitis, anal fissure/fistula/abscess, other fistula, and fever), the use of antidiarrheal medicines, presence of an abdominal mass, hematocrit, and body weight. These items are scored individually, weighted, and do not contribute equally to the overall score. The CDAI is derived from summing up the weighted individual scores of eight items. CDAI approximately ranges from 0 to 600 with higher scores indicating more severe disease.

    Time frame: Baseline and Week 12

  7. Percentage of Participants With Clinical Remission Per CDAI at Week 4

    CDAI is a composite instrument that includes participant symptoms evaluated over 7 days (abdominal pain, stool frequency and general well-being), as well as presence of complications (arthritis/arthralgia, iritis/uveitis, erythema nodosum/pyoderma gangrenosum/aphthous stomatitis, anal fissure/fistula/abscess, other fistula, and fever), the use of antidiarrheal medicines, presence of an abdominal mass, hematocrit, and body weight. These items are scored individually, weighted, and do not contribute equally to the overall score. The CDAI is derived from summing up the weighted individual scores of eight items. CDAI approximately ranges from 0 to 600 with higher scores indicating more severe disease. Clinical remission is defined as CDAI score less than 150.

    Time frame: Week 4

  8. Percentage of Participants With Hospitalizations Due to Crohn's Disease (CD) During the 12-Week Induction Period

    This was assessed by reviewing participant's hospitalization data.

    Time frame: 12 weeks

  9. Percentage of Participants With Resolution of Extra-Intestinal Manifestation (EIMs) at Week 12

    EIMs are defined as manifestations of Crohn's disease in areas of the body other than the digestive tract, including eyes, skin, joints, mouth, and liver. Only participants with any EIM present at Baseline were included in the analysis of resolution of EIMs. Resolution of EIMs was defined as absence of all EIMs at the Week 12 visit.

    Time frame: Week 12

  10. Percentage of Participants With Clinical Remission Per PROs at Week 4

    Clinical remission per PROs was defined as average daily very soft or liquid SF ≤ 2.8 and average daily APS ≤ 1.0 and neither worse than Baseline. Participants recorded APS and the number of liquid or very soft SF daily in an electronic diary. Abdominal pain was rated on a scale from 0 (none) to 3 (severe). The average daily very soft or liquid SF and APS were calculated using the 4-7 most recent useable days of patient-reported outcomes (i.e., excluding days with missing entries or associated with endoscopy procedures) out of the last 14 days prior to the Week 4 visit.

    Time frame: Week 4

  11. Percentage of Participants Who Discontinued Corticosteroid Use for Crohn's Disease and Achieved Clinical Remission Per PROs at Week 12

    Corticosteroid-free clinical remission is defined as participants who discontinued corticosteroid use for CD and achieved clinical remission per PROs at Week 12, assessed for participants taking corticosteroids for CD at Baseline. Clinical remission per PROs was defined as average daily very soft or liquid stool frequency (SF) ≤ 2.8 and average daily APS ≤ 1.0 and neither worse than Baseline. Participants recorded APS and the number of liquid or very soft SF daily in an electronic diary. Abdominal pain was rated on a scale from 0 (none) to 3 (severe). The average daily liquid or very soft SF and APS were calculated using the 4-7 most recent useable days of patient-reported outcomes (i.e., excluding days with missing entries or associated with endoscopy procedures) out of the last 14 days prior to the Week 12 visit.

    Time frame: Week 12

07

Results

Posted Nov 23, 2022

Participant flow

Eligible participants with moderately to severely active Crohn's disease (CD) were randomized at 209 sites in 42 countries. The study consisted of a 12-week double-blind induction treatment period, and a 12-week extended treatment period for participants who did not achieve clinical response at the end of the induction treatment period.

Part 1: Induction Period (Weeks 1-12)
Participant flow — Part 1: Induction Period (Weeks 1-12)
MilestonePart 1: PlaceboPart 1: Upadacitinib 45 mgPart 2: Placebo / Upadacitinib 45 mgPart 2: Upadacitinib 45 mg / Upadacitinib 30 mg
Started17635000
Received study drug17635000
Completed15433000
Not completed222000
Withdrew: Adverse event81200
Withdrew: Withdrawal by subject6300
Withdrew: Lost to follow-up0100
Withdrew: Lack of efficacy8300
Withdrew: Other0100
Part 2: Extended Treatment (Weeks 12-24)
Participant flow — Part 2: Extended Treatment (Weeks 12-24)
MilestonePart 1: PlaceboPart 1: Upadacitinib 45 mgPart 2: Placebo / Upadacitinib 45 mgPart 2: Upadacitinib 45 mg / Upadacitinib 30 mg
Started005759
Completed004949
Not completed00810
Withdrew: Adverse event0022
Withdrew: Withdrawal by subject0031
Withdrew: Lack of efficacy0015
Withdrew: Coronavirus disease-2019 (covid-19) infection0001
Withdrew: Covid-19 logistical restrictions0010
Withdrew: Other0011

Outcome measures

PrimaryPercentage of Participants With Clinical Remission Per Crohn's Disease Activity Index (CDAI) at Week 12

The co-primary endpoint for United States (US)/Food and Drug Administration (FDA) regulatory purposes was clinical remission based on CDAI at Week 12. CDAI is a composite instrument that includes participant symptoms evaluated over 7 days (abdominal pain, stool frequency and general well-being), as well as presence of complications (arthritis/arthralgia, iritis/uveitis, erythema nodosum/pyoderma gangrenosum/aphthous stomatitis, anal fissure/fistula/abscess, other fistula, and fever), the use of antidiarrheal medicines, presence of an abdominal mass, hematocrit, and body weight. These items are scored individually, weighted, and do not contribute equally to the overall score. The CDAI is derived from summing up the weighted individual scores of eight items. CDAI approximately ranges from 0 to 600 with higher scores indicating more severe disease. Clinical remission is defined as a CDAI score less than 150.

Time frame:
Week 12
Reported as:
Number · percentage of participants
Percentage of Participants With Clinical Remission Per Crohn's Disease Activity Index (CDAI) at Week 12
percentage of participantsPlaceboUpadacitinib 45 mg QD
Percentage of Participants With Clinical Remission Per Crohn's Disease Activity Index (CDAI) at Week 1229.1 (22.4 to 35.8)49.5 (44.2 to 54.8)
Statistical analysis
  • Placebo vs Upadacitinib 45 mg QD · Cochran-Mantel-Haenszel · p = <0.0001 · Adjusted response rate difference: 20.8 · 95% CI 12.7 to 28.8Adjusted response rate difference (Upadacitinib - Placebo) calculated based on CMH test adjusted for stratification factors.
PrimaryPercentage of Participants With Clinical Remission Per Patient-Reported Outcomes (PROs) at Week 12

The co-primary endpoint for European Union (EU)/European Medicines Agency (EMA) regulatory purposes was clinical remission defined based on two patient reported outcomes, average daily stool frequency (SF) and average daily abdominal pain score (APS). Clinical remission per PROs was defined as average daily very soft or liquid SF ≤ 2.8 and average daily APS ≤ 1.0 and neither worse than Baseline. Participants recorded APS and the number of very soft or liquid SF daily in an electronic diary. Abdominal pain was rated on a scale from 0 (none) to 3 (severe). The average daily very soft or liquid SF and APS were calculated using the 4-7 most recent useable days of patient-report outcomes (i.e., excluding days with missing entries or associated with endoscopy procedures) out of the last 14 days prior to the Week 12 visit.

Time frame:
Week 12
Reported as:
Number · percentage of participants
Percentage of Participants With Clinical Remission Per Patient-Reported Outcomes (PROs) at Week 12
percentage of participantsPlaceboUpadacitinib 45 mg QD
Percentage of Participants With Clinical Remission Per Patient-Reported Outcomes (PROs) at Week 1222.2 (16.0 to 28.3)50.7 (45.5 to 56.0)
Statistical analysis
  • Placebo vs Upadacitinib 45 mg QD · Cochran-Mantel-Haenszel · p = <0.0001 · Adjusted response rate difference: 28.7 · 95% CI 20.9 to 36.4Adjusted response rate difference (Upadacitinib - Placebo) calculated based on CMH test adjusted for stratification factors.
PrimaryPercentage of Participants With Endoscopic Response at Week 12

Endoscopic response at Week 12 was a co-primary endpoint for both the US/FDA and EU/EMA regulatory purposes. Endoscopic response was defined as greater than 50% decrease in Simple Endoscopic Score for Crohn's Disease (SES-CD) from Baseline of the induction study (or for participants with an SES-CD of 4 at Baseline, at least a 2-point reduction from Baseline), as scored by independent external and blinded central readers. The SES-CD evaluates 4 endoscopic variables (ulcer size, ulcerated surface, affected surface, and narrowing, each on a scale from 0 (none) to 3 in 5 segments assessed during ileocolonoscopy (ileum, right colon, transverse colon, sigmoid and left colon, and rectum). The total score is the sum of the 4 endoscopic variable scores and ranges from 0 to 56, where higher scores indicate more severe disease.

Time frame:
Baseline and Week 12
Reported as:
Number · percentage of participants
Percentage of Participants With Endoscopic Response at Week 12
percentage of participantsPlaceboUpadacitinib 45 mg QD
Percentage of Participants With Endoscopic Response at Week 1213.1 (8.1 to 18.0)45.5 (40.3 to 50.8)
Statistical analysis
  • Placebo vs Upadacitinib 45 mg QD · Cochran-Mantel-Haenszel · p = <0.0001 · Adjusted response rate difference: 33.0 · 95% CI 26.2 to 39.9Adjusted response rate difference (Upadacitinib - Placebo) calculated based on CMH test adjusted for stratification factors.
SecondaryPercentage of Participants With Endoscopic Remission at Week 12

Endoscopic remission is defined as an SES-CD ≤ 4 and at least 2 point reduction from Baseline and no subscore \> 1 in any individual variable,as scored by independent external and blinded central readers. The SES-CD evaluates 4 endoscopic variables (ulcer size, ulcerated surface, affected surface, and narrowing, each on a scale from 0 (none) to 3 in 5 segments assessed during ileocolonoscopy (ileum, right colon, transverse colon, sigmoid and left colon, and rectum). The total score is the sum of the 4 endoscopic variable scores and ranges from 0 to 56, where higher scores indicate more severe disease.

Time frame:
Baseline and Week 12
Reported as:
Number · percentage of participants
Percentage of Participants With Endoscopic Remission at Week 12
percentage of participantsPlaceboUpadacitinib 45 mg QD
Percentage of Participants With Endoscopic Remission at Week 127.4 (3.5 to 11.3)28.9 (24.2 to 33.7)
Statistical analysis
  • Placebo vs Upadacitinib 45 mg QD · Cochran-Mantel-Haenszel · p = <0.0001 · Adjusted response rate difference: 21.8 · 95% CI 15.8 to 27.8Adjusted response rate difference (Upadacitinib - Placebo) calculated based on CMH test adjusted for stratification factors.
SecondaryPercentage of Participants Who Discontinued Corticosteroid Use for Crohn's Disease and Achieved Clinical Remission Per CDAI at Week 12

Corticosteroid-free clinical remission is defined as participants who discontinued corticosteroid use for CD and achieved clinical remission per CDAI at Week 12, assessed for participants taking corticosteroids for CD at Baseline. CDAI is a composite instrument that includes participant symptoms evaluated over 7 days (abdominal pain, stool frequency and general well-being), as well as presence of complications (arthritis/arthralgia, iritis/uveitis, erythema nodosum/pyoderma gangrenosum/aphthous stomatitis, anal fissure/fistula/abscess, other fistula, and fever), the use of antidiarrheal medicines, presence of an abdominal mass, hematocrit, and body weight. These items are scored individually, weighted, and do not contribute equally to the overall score. The CDAI is derived from summing up the weighted individual scores of eight items. CDAI approximately ranges from 0 to 600 with higher scores indicating more severe disease. Clinical remission is defined as CDAI score less than 150.

Time frame:
Week 12
Reported as:
Number · percentage of participants
Percentage of Participants Who Discontinued Corticosteroid Use for Crohn's Disease and Achieved Clinical Remission Per CDAI at Week 12
percentage of participantsPlaceboUpadacitinib 45 mg QD
Percentage of Participants Who Discontinued Corticosteroid Use for Crohn's Disease and Achieved Clinical Remission Per CDAI at Week 1215.7 (6.8 to 24.7)42.9 (34.2 to 51.5)
Statistical analysis
  • Placebo vs Upadacitinib 45 mg QD · Cochran-Mantel-Haenszel · p = <0.0001 · Adjusted response rate difference: 27.7 · 95% CI 15.7 to 39.8Adjusted response rate difference (Upadacitinib - Placebo) calculated based on CMH test adjusted for stratification factors endoscopic disease severity and number of prior biologic failed.
SecondaryChange From Baseline in Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-Fatigue) at Week 12

The FACIT-Fatigue questionnaire is a self-administered patient questionnaire that consists of 13 questions designed to measure the degree of fatigue experienced by participants in the previous 7 days, including physical fatigue (e.g., I feel tired), functional fatigue (e.g., trouble finishing things), emotional fatigue (e.g., frustration), and social consequences of fatigue (e.g., limits social activity). Participants respond to the questions on a scale from 0 (not at all) to 4 (very much). The FACIT-Fatigue score is computed by summing the item scores, after reversing those items that are worded in the negative direction. The FACIT-Fatigue score ranges from 0 to 52, where higher scores represent less fatigue. A positive change from Baseline indicates improvement.

Time frame:
Baseline and Week 12
Reported as:
Least squares mean · score on a scale
Change From Baseline in Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-Fatigue) at Week 12
score on a scalePlaceboUpadacitinib 45 mg QD
Change From Baseline in Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-Fatigue) at Week 125.0 (3.2 to 6.8)11.3 (10.0 to 12.5)
Statistical analysis
  • Placebo vs Upadacitinib 45 mg QD · Mixed-effect Model Repeated Measurement · p = <0.0001 · Least squares (ls) mean difference: 6.3 · 95% CI 4.2 to 8.3MMRM model with fixed effects of treatment, visit, and treatment-by-visit interaction, stratification factors, and Baseline value as covariate.
SecondaryChange From Baseline in Inflammatory Bowel Disease Questionnaire (IBDQ) Total Score at Week 12

The Inflammatory Bowel Disease Questionnaire (IBDQ) is used to assess health-related quality of life (HRQoL) in patients with inflammatory bowel disease. It consists of 32 questions evaluating bowel and systemic symptoms, as well as emotional and social functions. Each question is answered on a scale from 1 (worst) to 7 (best). The total score ranges from 32 to 224 with higher scores indicating better health-related quality of life. A positive change from Baseline indicates improvement.

Time frame:
Baseline and Week 12
Reported as:
Least squares mean · score on a scale
Change From Baseline in Inflammatory Bowel Disease Questionnaire (IBDQ) Total Score at Week 12
score on a scalePlaceboUpadacitinib 45 mg QD
Change From Baseline in Inflammatory Bowel Disease Questionnaire (IBDQ) Total Score at Week 1224.423 (19.007 to 29.840)46.265 (42.495 to 50.035)
Statistical analysis
  • Placebo vs Upadacitinib 45 mg QD · Mixed-effect Model Repeated Measurement · p = <0.0001 · Ls mean difference: 21.842 · 95% CI 15.566 to 28.118MMRM model with fixed effects of treatment, visit, and treatment-by-visit interaction, stratification factors, and Baseline value as covariate.
SecondaryPercentage of Participants Achieving Clinical Response 100 (CR-100) at Week 2

Clinical response 100 (CR-100) is defined as a decrease of at least 100 points in CDAI from Baseline. CDAI is a composite instrument that includes participant symptoms evaluated over 7 days (abdominal pain, stool frequency and general well-being), as well as presence of complications (arthritis/arthralgia, iritis/uveitis, erythema nodosum/pyoderma gangrenosum/aphthous stomatitis, anal fissure/fistula/abscess, other fistula, and fever), the use of antidiarrheal medicines, presence of an abdominal mass, hematocrit, and body weight. These items are scored individually, weighted, and do not contribute equally to the overall score. The CDAI is derived from summing up the weighted individual scores of eight items. CDAI approximately ranges from 0 to 600 with higher scores indicating more severe disease.

Time frame:
Baseline and Week 2
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Clinical Response 100 (CR-100) at Week 2
percentage of participantsPlaceboUpadacitinib 45 mg QD
Percentage of Participants Achieving Clinical Response 100 (CR-100) at Week 220.4 (14.4 to 26.5)32.2 (27.3 to 37.1)
Statistical analysis
  • Placebo vs Upadacitinib 45 mg QD · Cochran-Mantel-Haenszel · p = 0.0022 · Adjusted response rate difference: 11.7 · 95% CI 4.2 to 19.2Adjusted response rate difference (Upadacitinib - Placebo) calculated based on CMH test adjusted for stratification factors.
SecondaryPercentage of Participants Achieving Clinical Response 100 (CR-100) at Week 12

Clinical response 100 (CR-100) is defined as a decrease of at least 100 points in CDAI from Baseline. CDAI is a composite instrument that includes participant symptoms evaluated over 7 days (abdominal pain, stool frequency and general well-being), as well as presence of complications (arthritis/arthralgia, iritis/uveitis, erythema nodosum/pyoderma gangrenosum/aphthous stomatitis, anal fissure/fistula/abscess, other fistula, and fever), the use of antidiarrheal medicines, presence of an abdominal mass, hematocrit, and body weight. These items are scored individually, weighted, and do not contribute equally to the overall score. The CDAI is derived from summing up the weighted individual scores of eight items. CDAI approximately ranges from 0 to 600 with higher scores indicating more severe disease.

Time frame:
Baseline and Week 12
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Clinical Response 100 (CR-100) at Week 12
percentage of participantsPlaceboUpadacitinib 45 mg QD
Percentage of Participants Achieving Clinical Response 100 (CR-100) at Week 1237.3 (30.1 to 44.5)56.6 (51.4 to 61.8)
Statistical analysis
  • Placebo vs Upadacitinib 45 mg QD · Cochran-Mantel-Haenszel · p = <0.0001 · Adjusted response rate difference: 19.8 · 95% CI 11.3 to 28.4Adjusted response rate difference (Upadacitinib - Placebo) calculated based on CMH test adjusted for stratification factors.
SecondaryPercentage of Participants With Clinical Remission Per CDAI at Week 4

CDAI is a composite instrument that includes participant symptoms evaluated over 7 days (abdominal pain, stool frequency and general well-being), as well as presence of complications (arthritis/arthralgia, iritis/uveitis, erythema nodosum/pyoderma gangrenosum/aphthous stomatitis, anal fissure/fistula/abscess, other fistula, and fever), the use of antidiarrheal medicines, presence of an abdominal mass, hematocrit, and body weight. These items are scored individually, weighted, and do not contribute equally to the overall score. The CDAI is derived from summing up the weighted individual scores of eight items. CDAI approximately ranges from 0 to 600 with higher scores indicating more severe disease. Clinical remission is defined as CDAI score less than 150.

Time frame:
Week 4
Reported as:
Number · percentage of participants
Percentage of Participants With Clinical Remission Per CDAI at Week 4
percentage of participantsPlaceboUpadacitinib 45 mg QD
Percentage of Participants With Clinical Remission Per CDAI at Week 426.7 (20.2 to 33.3)37.1 (32.1 to 42.2)
Statistical analysis
  • Placebo vs Upadacitinib 45 mg QD · Cochran-Mantel-Haenszel · p = 0.0071 · Adjusted response rate difference: 10.8 · 95% CI 2.9 to 18.6Adjusted response rate difference (Upadacitinib - Placebo) calculated based on CMH test adjusted for stratification factors.
SecondaryPercentage of Participants With Hospitalizations Due to Crohn's Disease (CD) During the 12-Week Induction Period

This was assessed by reviewing participant's hospitalization data.

Time frame:
12 weeks
Reported as:
Number · percentage of participants
Percentage of Participants With Hospitalizations Due to Crohn's Disease (CD) During the 12-Week Induction Period
percentage of participantsPlaceboUpadacitinib 45 mg QD
Percentage of Participants With Hospitalizations Due to Crohn's Disease (CD) During the 12-Week Induction Period5.1 (1.9 to 8.4)3.7 (1.7 to 5.7)
Statistical analysis
  • Placebo vs Upadacitinib 45 mg QD · Chi-squared · p = 0.4494 · Response rate difference: -1.4 · 95% CI -5.2 to 2.4Response rate difference = Upadacitinib - Placebo
SecondaryPercentage of Participants With Resolution of Extra-Intestinal Manifestation (EIMs) at Week 12

EIMs are defined as manifestations of Crohn's disease in areas of the body other than the digestive tract, including eyes, skin, joints, mouth, and liver. Only participants with any EIM present at Baseline were included in the analysis of resolution of EIMs. Resolution of EIMs was defined as absence of all EIMs at the Week 12 visit.

Time frame:
Week 12
Reported as:
Number · percentage of participants
Percentage of Participants With Resolution of Extra-Intestinal Manifestation (EIMs) at Week 12
percentage of participantsPlaceboUpadacitinib 45 mg QD
Percentage of Participants With Resolution of Extra-Intestinal Manifestation (EIMs) at Week 1220.9 (11.8 to 30.1)28.5 (21.3 to 35.7)
Statistical analysis
  • Placebo vs Upadacitinib 45 mg QD · Cochran-Mantel-Haenszel · p = 0.1044 · Adjusted response rate difference: 9.0 · 95% CI -1.9 to 19.9Adjusted response rate difference (Upadacitinib - Placebo) calculated based on CMH test adjusted for stratification factors.
SecondaryPercentage of Participants With Clinical Remission Per PROs at Week 4

Clinical remission per PROs was defined as average daily very soft or liquid SF ≤ 2.8 and average daily APS ≤ 1.0 and neither worse than Baseline. Participants recorded APS and the number of liquid or very soft SF daily in an electronic diary. Abdominal pain was rated on a scale from 0 (none) to 3 (severe). The average daily very soft or liquid SF and APS were calculated using the 4-7 most recent useable days of patient-reported outcomes (i.e., excluding days with missing entries or associated with endoscopy procedures) out of the last 14 days prior to the Week 4 visit.

Time frame:
Week 4
Reported as:
Number · percentage of participants
Percentage of Participants With Clinical Remission Per PROs at Week 4
percentage of participantsPlaceboUpadacitinib 45 mg QD
Percentage of Participants With Clinical Remission Per PROs at Week 414.8 (9.5 to 20.0)35.7 (30.7 to 40.7)
Statistical analysis
  • Placebo vs Upadacitinib 45 mg QD · Cochran-Mantel-Haenszel · p = <0.0001 · Adjusted response rate difference: 21.2 · 95% CI 14.3 to 28.2Adjusted response rate difference (Upadacitinib - Placebo) calculated based on CMH test adjusted for stratification factors.
SecondaryPercentage of Participants Who Discontinued Corticosteroid Use for Crohn's Disease and Achieved Clinical Remission Per PROs at Week 12

Corticosteroid-free clinical remission is defined as participants who discontinued corticosteroid use for CD and achieved clinical remission per PROs at Week 12, assessed for participants taking corticosteroids for CD at Baseline. Clinical remission per PROs was defined as average daily very soft or liquid stool frequency (SF) ≤ 2.8 and average daily APS ≤ 1.0 and neither worse than Baseline. Participants recorded APS and the number of liquid or very soft SF daily in an electronic diary. Abdominal pain was rated on a scale from 0 (none) to 3 (severe). The average daily liquid or very soft SF and APS were calculated using the 4-7 most recent useable days of patient-reported outcomes (i.e., excluding days with missing entries or associated with endoscopy procedures) out of the last 14 days prior to the Week 12 visit.

Time frame:
Week 12
Reported as:
Number · percentage of participants
Percentage of Participants Who Discontinued Corticosteroid Use for Crohn's Disease and Achieved Clinical Remission Per PROs at Week 12
percentage of participantsPlaceboUpadacitinib 45 mg QD
Percentage of Participants Who Discontinued Corticosteroid Use for Crohn's Disease and Achieved Clinical Remission Per PROs at Week 1212.5 (4.4 to 20.6)44.4 (35.8 to 53.1)
Statistical analysis
  • Placebo vs Upadacitinib 45 mg QD · Cochran-Mantel-Haenszel · p = <0.0001 · Adjusted response rate difference: 32.6 · 95% CI 21.5 to 43.7Adjusted response rate difference (Upadacitinib - Placebo) calculated based on CMH test adjusted for stratification factors.

Adverse events

Collected over Part 1: 12 weeks Part 2: 12 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part 1: Placebo0/176 (0%)12/176 (6.8%)37/176 (21%)
Part 1: Upadacitinib 45 mg0/350 (0%)24/350 (6.9%)92/350 (26.3%)
Part 2: Placebo / Upadacitinib 45 mg0/57 (0%)4/57 (7%)14/57 (24.6%)
Part 2: Upadacitinib 45 mg / Upadacitinib 30 mg1/59 (1.7%)6/59 (10.2%)13/59 (22%)
Most frequent serious events
Showing 10 of 38
Most frequent serious events
EventPart 1: PlaceboPart 1: Upadacitinib 45 mgPart 2: Placebo / Upadacitinib 45 mgPart 2: Upadacitinib 45 mg / Upadacitinib 30 mg
CROHN'S DISEASEGastrointestinal disorders5/1767/3501/572/59
INTESTINAL PERFORATIONGastrointestinal disorders0/1760/3501/570/59
COVID-19 PNEUMONIAInfections and infestations1/1760/3501/570/59
FALLInjury, poisoning and procedural complications0/1760/3501/570/59
FEMORAL NECK FRACTUREInjury, poisoning and procedural complications0/1760/3501/570/59
ACUTE RESPIRATORY FAILURERespiratory, thoracic and mediastinal disorders0/1760/3501/570/59
ENTERITISGastrointestinal disorders0/1760/3500/571/59
INTESTINAL OBSTRUCTIONGastrointestinal disorders0/1762/3500/571/59
COVID-19Infections and infestations0/1760/3500/571/59
GASTROENTERITIS VIRALInfections and infestations0/1760/3500/571/59
Most frequent other events
Most frequent other events
EventPart 1: PlaceboPart 1: Upadacitinib 45 mgPart 2: Placebo / Upadacitinib 45 mgPart 2: Upadacitinib 45 mg / Upadacitinib 30 mg
CROHN'S DISEASEGastrointestinal disorders13/1765/3501/573/59
ACNESkin and subcutaneous tissue disorders1/17624/3503/571/59
NASOPHARYNGITISInfections and infestations6/17616/3502/574/59
ANAEMIABlood and lymphatic system disorders8/17621/3503/572/59
COVID-19Infections and infestations0/1763/3503/571/59
ARTHRALGIAMusculoskeletal and connective tissue disorders8/1769/3503/571/59
RASHSkin and subcutaneous tissue disorders4/17613/3503/571/59
PYREXIAGeneral disorders2/17614/3501/573/59

Baseline characteristics

Intention-to-treat (ITT) population for the 12-week double-blind induction period includes all randomized participants who received at least one dose of double-blind study drug during Part 1.

Age, Continuous
Age, Continuous(years)PlaceboUpadacitinib 45 mgTotal
Mean39.3 ± 13.6339.7 ± 13.7139.6 ± 13.67
Age, Customized
Age, Customized(Participants)PlaceboUpadacitinib 45 mgTotal
18 years - < 40 years91193284
40 years - < 65 years80142222
≥ 65 years51520
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboUpadacitinib 45 mgTotal
Female82161243
Male94189283
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PlaceboUpadacitinib 45 mgTotal
Hispanic or Latino82735
Not Hispanic or Latino168323491
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PlaceboUpadacitinib 45 mgTotal
American Indian or Alaska Native000
Asian3673109
Native Hawaiian or Other Pacific Islander000
Black or African American41721
White130258388
More than one race628
Unknown or Not Reported000
Baseline Corticosteroid Use
Baseline Corticosteroid Use(Participants)PlaceboUpadacitinib 45 mgTotal
Yes64126190
No112224336
Number of Previously Failed Biologics
Number of Previously Failed Biologics(Participants)PlaceboUpadacitinib 45 mgTotal
Zero98189287
One285886
More than one50103153
Endoscopic Disease Severity
Endoscopic Disease Severity(Participants)PlaceboUpadacitinib 45 mgTotal
SES-CD < 15110218328
SES-CD ≥ 1566132198

4 further baseline measures are reported on the registry.

08

Study locations

432 sites
  • East View Medical Research, LLC /ID# 171176
    Mobile, Alabama 36606, United States
  • CB Flock Research Corporation /ID# 166185
    Mobile, Alabama 36608, United States
  • Delsol Research Management, Ll /Id# 170145
    Chandler, Arizona 85224, United States
  • HonorHealth Research Institute - Shea /ID# 164821
    Scottsdale, Arizona 85258, United States
  • Arizona Arthritis & Rheumatology Research, PLLC /ID# 164803
    Sun City, Arizona 85306, United States
  • Southern California Res. Ctr. /ID# 169655
    Coronado, California 92118-1408, United States
  • Citrus Valley Gastroenterology /ID# 166173
    Covina, California 91722-3797, United States
  • Hoag Memorial Hosp Presbyterian /ID# 222540
    Irvine, California 92618, United States
  • United Medical Doctors /ID# 207449
    Los Alamitos, California 90720-3309, United States
  • Gastrointestinal Biosciences Clinical Trials, LLC /ID# 164762
    Los Angeles, California 90067-2001, United States
  • Facey Medical Foundation /ID# 203136
    Mission Hills, California 91345, United States
  • United Medical Doctors - Murrieta /ID# 164945
    Murrieta, California 92563, United States
  • Ucsd /Id# 164910
    San Diego, California 92103, United States
  • Medical Assoc Research Grp /ID# 169706
    San Diego, California 92123, United States
  • Univ of California San Francis /ID# 164944
    San Francisco, California 94158, United States
  • Care Access Research /ID# 167767
    San Pablo, California 94806, United States
  • Peak Gastroenterology Associates, PC /ID# 170143
    Colorado Springs, Colorado 80907, United States
  • Delta Waves, Inc. /ID# 164776
    Colorado Springs, Colorado 80918, United States
  • Western States Clinical Res /ID# 164760
    Wheat Ridge, Colorado 80033-2896, United States
  • Medical Research Center of CT /ID# 164926
    Hamden, Connecticut 06518, United States
  • Clinical Research of West Florida, Inc /ID# 205827
    Clearwater, Florida 33765, United States
  • Clinical Research of West Florida, Inc /ID# 208118
    Clearwater, Florida 33765, United States
  • Advanced Research - Coral Springs /ID# 218021
    Coral Springs, Florida 33067-3173, United States
  • Encore Borland-Groover Clinical Research /Id# 203499
    Jacksonville, Florida 32256, United States
  • Ctr for Advanced Gastroenterol /ID# 165353
    Maitland, Florida 32751-6108, United States
  • Crystal Pharmacology Research /ID# 166081
    Miami, Florida 33165, United States
  • Coral Research Clinic /ID# 164890
    Miami, Florida 33186-4643, United States
  • Advanced Research Institute, Inc /ID# 164921
    New Port Richey, Florida 34653, United States
  • Endoscopic Research, Inc. /ID# 206136
    Orlando, Florida 32803, United States
  • Omega Research Maitland, LLC /ID# 203481
    Orlando, Florida 32808, United States
  • Clinical Research Trials of Florida, Inc. /ID# 203485
    Tampa, Florida 33607, United States
  • AdventHealth Tampa /ID# 171167
    Tampa, Florida 33613-4680, United States
  • Gastroenterology Associates of Central Georgia, LLC /ID# 165478
    Macon, Georgia 31201, United States
  • Gastroenterology Consultants PC - Roswell /ID# 218220
    Roswell, Georgia 30076-4913, United States
  • Atlanta Gastroenterology Spec /ID# 164799
    Suwanee, Georgia 30024, United States
  • Treasure Valley Medical Research /ID# 215032
    Boise, Idaho 83706, United States
  • Rush University Medical Center /ID# 165497
    Chicago, Illinois 60612, United States
  • University of Chicago Medicine /ID# 165503
    Chicago, Illinois 60637-1426, United States
  • DuPage Medical Group /ID# 205328
    Downers Grove, Illinois 60515-5509, United States
  • MediSphere Medical Research Center /ID# 166175
    Evansville, Indiana 47714-8011, United States
  • Indianapolis Gastroenterology /ID# 164938
    Indianapolis, Indiana 46237, United States
  • University of Iowa Hospitals and Clinics /ID# 165436
    Iowa City, Iowa 52242, United States
  • Tri-State Gastroenterology /ID# 165496
    Crestview Hills, Kentucky 41017, United States
  • University of Louisville /ID# 165366
    Louisville, Kentucky 40202, United States
  • University of Louisville /ID# 168572
    Louisville, Kentucky 40202, United States
  • CroNOLA, LLC /ID# 164823
    Houma, Louisiana 70360, United States
  • Nola Research Works, LLC /ID# 164759
    New Orleans, Louisiana 70115, United States
  • Louisana Research Center, LLC /ID# 164894
    Shreveport, Louisiana 71105-6800, United States
  • Johns Hopkins University School of Medicine /ID# 211941
    Baltimore, Maryland 21287-0010, United States
  • MGG Group Co, Inc.Chevy Chase Clinical Research /ID# 164935
    Chevy Chase, Maryland 20815, United States
  • Gastro Center of Maryland /ID# 171161
    Columbia, Maryland 21045, United States
  • Lahey Hospital and Medical Center /ID# 214726
    Burlington, Massachusetts 01805, United States
  • University of Michigan Comprehensive Cancer Center Michigan Medicine /ID# 164943
    Ann Arbor, Michigan 48109, United States
  • Digestive Health Associates (DHA) - Farmington Hills /ID# 205793
    Farmington Hills, Michigan 48334-3230, United States
  • Center for Digestive Health /ID# 164822
    Troy, Michigan 48098-6363, United States
  • Clin Res Inst of Michigan, LLC /ID# 170133
    Troy, Michigan 48098, United States
  • Mayo Clinic - Rochester /ID# 164783
    Rochester, Minnesota 55905-0001, United States
  • Southern Therapy and Advanced Research (STAR) LLC /ID# 165343
    Jackson, Mississippi 39216, United States
  • Quality Clinical Research Inc. /ID# 170137
    Omaha, Nebraska 68114-3723, United States
  • Duplicate_CHI Nebraska d/b/a CHI Health /ID# 168578
    Omaha, Nebraska 68124, United States
  • Las Vegas Medical Research /ID# 168588
    Las Vegas, Nevada 89113, United States
  • AGA Clinical Research Associates, LLC /ID# 164769
    Egg Harbor Township, New Jersey 08234, United States
  • Rutgers Robert Wood Johnson /ID# 166073
    New Brunswick, New Jersey 08901, United States
  • Montefiore Medical Center - Moses Campus /ID# 166193
    Bronx, New York 10467, United States
  • Advantage Clinical Trials /ID# 168546
    Bronx, New York 10468, United States
  • NY Scientific /ID# 164931
    Brooklyn, New York 11235, United States
  • United Health Services Hospitals, Inc /ID# 217485
    Johnson City, New York 13790-2107, United States
  • NYU Langone Long Island Clinical Research Associates /ID# 164927
    Lake Success, New York 11042, United States
  • The Mount Sinai Hospital /ID# 170257
    New York, New York 10029, United States
  • Columbia Univ Medical Center /ID# 164782
    New York, New York 10032-3725, United States
  • Gastoenterology Group of Rochester /ID# 166177
    Rochester, New York 14618-5703, United States
  • Richmond University Medical Center /ID# 201857
    Staten Island, New York 10310-1664, United States
  • Atrium Health Carolinas Medical Center /ID# 164932
    Charlotte, North Carolina 28203, United States
  • PMG Research of Charlotte /ID# 171160
    Charlotte, North Carolina 28209, United States
  • Wake Radiology UNC REX Healthcare - Raleigh Office /ID# 164904
    Raleigh, North Carolina 27612, United States
  • Wake Forest Baptist Medical Center /ID# 164908
    Winston-Salem, North Carolina 27157-0001, United States
  • Plains Clinical Research Center, LLC /ID# 170140
    Fargo, North Dakota 58104-5925, United States
  • Gastro Health Research /ID# 164791
    Cincinnati, Ohio 45219, United States
  • University of Cincinnati /ID# 164825
    Cincinnati, Ohio 45267-0585, United States
  • Cleveland Clinic Main Campus /ID# 209231
    Cleveland, Ohio 44195, United States
  • The Ohio State University /ID# 170141
    Columbus, Ohio 43210, United States
  • Optimed Research, Ltd. /ID# 205624
    Columbus, Ohio 43235, United States
  • Hometown Urgent Care and Resea /ID# 201291
    Dayton, Ohio 45424, United States
  • Dayton Gastroenterology, Inc. /ID# 167627
    Englewood, Ohio 45415, United States
  • Great Lakes Medical Research, LLC /ID# 202010
    Mentor, Ohio 44060-6211, United States
  • Digestive Disease Specialists /ID# 201064
    Oklahoma City, Oklahoma 73112, United States
  • Options Health Research, LLC /ID# 164820
    Tulsa, Oklahoma 74104, United States
  • Healthcare Research Consultant /ID# 166195
    Tulsa, Oklahoma 74135, United States
  • University of Pennsylvania /ID# 168430
    Philadelphia, Pennsylvania 19104-5502, United States
  • Pharmacorp Clinical Trials /ID# 164916
    Charleston, South Carolina 29412, United States
  • Gastroenterology Associates, P.A. of Greenville /ID# 164771
    Greenville, South Carolina 29615-3593, United States
  • Rapid City Medical Center - GI Research /ID# 201735
    Rapid City, South Dakota 57701, United States
  • Gastro One /ID# 164826
    Germantown, Tennessee 38138, United States
  • East Tennessee Research Institute /ID# 203613
    Johnson City, Tennessee 37604, United States
  • Quality Medical Research /ID# 205263
    Nashville, Tennessee 37211, United States
  • Vanderbilt University Medical Center /ID# 164946
    Nashville, Tennessee 37232-0011, United States
  • TX Clinical Research Institute /ID# 164896
    Arlington, Texas 76012, United States
  • Inquest Clinical Research /ID# 164785
    Baytown, Texas 77521-2415, United States
  • Texas Digestive Disease Consultants /ID# 209953
    Cedar Park, Texas 78613-5028, United States
  • Texas Digestive Disease Consultants /ID# 209801
    Cedar Park, Texas 78613, United States

Showing the first 100 of 432 sites across 49 countries. Choose a country and city above to see the rest.

09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols, analyses plans, clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: For details on when studies are available for sharing visit https://vivli.org/ourmember/abbvie/

Access criteria: Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous independent scientific research, and will be provided following review and approval of a research proposal and statistical analysis plan and execution of a data sharing statement. Data requests can be submitted at any time after approval in the US and/or EU and a primary manuscript is accepted for publication. For more information on the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2017 to primary completion in Oct 2021, 46 months.

Results were first posted in Nov 2022, 1 year 1 month after primary completion.

Of 70 industry-sponsored phase 3 interventional studies under Crohn Disease, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 35 and three quarters within 69. This study's 46 months is close to that.

Counting every sponsor, half of 88 studies reached it within 49 months; a quarter within 36 and three quarters within 69.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 15, 2017
First posted
Nov 17, 2017
StartActual
Dec 7, 2017
Primary completionActual
Oct 15, 2021
CompletionActual
Jan 13, 2022
Results first posted
Nov 23, 2022
Last update
Nov 23, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 23, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03345849
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Nov 17, 2017
Start date
Dec 7, 2017
Primary completion
Oct 15, 2021
Completion
Jan 13, 2022
Results posted
Nov 23, 2022
Last update
Nov 23, 2022

Study contacts

ABBVIE INC.
study director · AbbVie

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Upadacitinib

Start the discussion